Combination treatment using cavitated Panavir solution in patients with HPV-associated cervical intraepithelial neoplasia

Kononova I.N.; Oboskalova T.A.; Voroshilina E.S.; Kuzina T.V.

doi:https://doi.org/10.17116/rosakush201717571-74

Kononova I.N.

Kafedra akusherstva i ginekologii

Oboskalova T.A.

Kafedra akusherstva i ginekologii

Voroshilina E.S.

Ural'skaia gosudarstvennaia meditsinskaia akademiia

Kuzina T.V.

Tsentral'naia gorodskaia bol'nitsa # 7, Ekaterinburg

Combination treatment using cavitated Panavir solution in patients with HPV-associated cervical intraepithelial neoplasia

Authors:

Kononova I.N., Oboskalova T.A., Voroshilina E.S., Kuzina T.V.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2017;17(5): 71‑74

DOI: 10.17116/rosakush201717571-74

Read: 1159 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kononova IN, Oboskalova TA, Voroshilina ES, Kuzina TV. Combination treatment using cavitated Panavir solution in patients with HPV-associated cervical intraepithelial neoplasia. Russian Bulletin of Obstetrician-Gynecologist. 2017;17(5):71‑74. (In Russ.)
https://doi.org/10.17116/rosakush201717571-74

Подписка 2026 Российский вестник акушера-гинеколога (Russian Bulletin of Obstetrician-Gynecologist)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Modern methods of treatment of latent form of HPV infection: clinical observation. Russian Journal of Clinical Dermatology and Venereology. 2025;(4):425-429

Abstract:

Objective: to investigate the clinical efficacy of a low-frequency ultrasound-cavitated intravaginal solution of the antiviral drug Panavir as part of the combination treatment of patients with cervical intraepithelial neoplasia (CIN I) associated with high-risk human papillomavirus. Subjects and methods. 60 patients with СIN I associated with high-risk human papillomavirus were examined and treated; 30 patients received therapy with low-frequency ultrasound-cavitated Panavir solutions (Group 1); 30 had standard treatment with a destruction technique (Group 2). Results. Combination therapy involving the local use of the cavitated solution of the antiviral drug Panavir was found to promote the elimination of human papilloma virus, to optimize the production of interferons, to accelerate reparative processes without destruction, and to reduce the recurrences of CIN I recurrences. Conclusion. The findings allow this method to be recommended for the treatment of patients with CIN I associated with high-risk human papillomavirus.

Keywords:

cervical neoplasias

human papillomavirus infection

low-frequency ultrasound

antiviral therapy

low-frequency ultrasound-cavitated Panavir solution

Authors:

Kononova I.N.

Kafedra akusherstva i ginekologii

Oboskalova T.A.

Kafedra akusherstva i ginekologii

Voroshilina E.S.

Ural'skaia gosudarstvennaia meditsinskaia akademiia

Kuzina T.V.

Tsentral'naia gorodskaia bol'nitsa # 7, Ekaterinburg

Close metadata

References:

Axel EM. Incidence and mortality from malignant tumors of the female reproductive system in Russia. Onkoginekologiya. 2015; 1: 6—15. (In Russ.)
Comprehensive cervical cancer control: a brief guide to essential practice. VOZ. 2010; 278. (In Russ.)
Prilepskaya VN, Bebneva TN. Rol’ virusa papillomy cheloveka v razvitii raka sheiki matki. (The role of human papillomavirus in cervical cancer). Profilaktika raka sheiki matki: sb. nauch. tr. Ed. G.T. Sukhikh, V.N. Prilepskaya. Moscow: Medpress-inform. 2012; 25—29. (In Russ.)
Rogovskaya SI. Papillomavirusnaya infektsiya u zhenshchin i patologiya sheiki matki. (Human papillomavirus infection in women and cervical pathology). Moscow: GEOTAR-Media. 2011; 190. (In Russ.)
Doorbar J. Molecular biology of human papilloma virus infection and cervical cancer. Clinical Science. 2006; 110: 525—541. https://doi.org/10.1042/cs20050369
Abramovskikh OS, Zotova MA, Telesheva LF. Analiz spektra genotipov virusa papillomy cheloveka vysokogo kantserogennogo riska pri tservikal’noi patologii. (Spectrum fnalysis of the genotypes of human papillomavirus of high carcinogenic risk in cervical pathology). Materialy II Ezhegodnogo Vserossiiskogo kongressa po infektsionnym boleznyam. M. 2010; 4. (In Russ.)
Andosova LD, Kontorshchikova KN, Kudelkina SYu, Blatova OL, Mikhaleva OV, Kuznetsova IA, Baikova RA. Gene diagnostics of high cancer risk papillomavirus infection. Rossiiskii vestnik akushera-ginekologa. 2011; 11: 2: 13—15. (In Russ.)
Zolotoverkhaya EA, Shipitsina EV, Yushmanova ES, Kostyuchek IN, Evstigneeva LA, Savicheva AM. Oncogenic types of human papillomavirus in women with cervical pathology. Zhurnal akusherstva i zhenskikh boleznei. 2009; VIII: 5: 83—89. (In Russ.)
Kononova IN, Voroshilina ES. Immunological and molecular genetic parallels of HPV-associated CIN, methods of correction. Immunologiya i allergologiya. 2014; 15: 4: 298—299. (In Russ.)
Bosch FX, Burchell AN, Sciffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Muñoz N. Epidemiology and natural history of human papillomavirus infection and type-specific implications in cervical neoplasia. Vaccine. 2008; 24: 10: 1—16. https://doi.org/10.1016/j.vaccine.2008.05.064
Clifford G, Rana RK, Franceschi S, Smith J, Gough G, Pimenta JM. Human papilloma virus genotype distribution in low-grade cervical lesions: comparison by geographic region and cervical cancer. Cancer Epidemiological Biomarker. 2005; 14: 1157—1164. https://doi.org/10.1158/1055-9965.epi-04-0812
Muñoz N, Bosch FX, de Sanjose S, Herrero R, Castellsagué X, Shah KV, Snijders PJF, Meijer CJLM. Epidemiologic classification of human papilloma virus types associated with cervical cancer. New England Journal of Medicine. 2003; 348: 518—527. https://doi.org/10.1056/nejmoa021641
Zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology. 1991; 184: 1: 9-1. https://doi.org/10.1016/0042-6822(91)90816-t
Gizinger OA, Letyaeva OI. Possibilities of correction of immunobiological dysfunctions of the lower section of the reproductive tract. Vestnik Chelyabinskogo gosudarstvennogo universiteta. (Biologiya ; vyp. 2). 2013; 7: 298: 12—13. (In Russ.)
Kononova IN., Oboskalova TA, Voroshilina ES. Effective therapy of hpv infection using peptide regulator of immunity, cavitating frequency ultrasound in patients with cervical intraepithelial neoplasia. Rossiiskii immunologicheskii zhurnal. 2014; 8: 17: 3: 699—701. (In Russ.)
Kononova IN, Voroshilina ES. Features local immunity in cervical intraepithelial neoplasia associated with hpv infection. 2014. Rossiiskii immunologicheskii zhurnal. 2014; 8: 17: 3: 809—811. (In Russ.)
Stern PL. Immune control of human papilloma virus (HPV) associated anogenital disease and potential for vaccination. Journal of Clinical VIROLOGY.2005; 32S1:S72-S81. https://doi.org/10.1016/j.jcv.2004.12.005
Oboskalova TA, Kononova IN, Voroshilina ES, Kuzina TV, Stovbun SV, Safronov DYu., Kucherov VA, Bagaeva MI. Efficiency of antiviral therapy in the combination treatment of patients with HPV-associated cervical neoplasias. Rossiiskii vestnik akushera-ginekologa. 2013; 1: 70—72. (In Russ.)
Ueda H, Mutoh M, Seki T, Kobayashi D, Morimoto Y. Acoustic cavitation as an enhancing mechanism of low-frequency sonophoresis for transdermal drug delivery. Biol Pharm Bull. 2009; 32: 5: 916—920. https://doi.org/10.1248/bpb.32.916